# Using Plant-Derived Chemicals and Metabolic Drugs to Fight Cancer

> A medical patent describing a combination therapy that pairs specific plant-derived compounds with metabolic drugs to kill cancer cells more effectively than either could alone.

- **Patent:** US RE46907
- **Original title:** USRE46907E1 - Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
- **Owner:** Johns Hopkins University
- **Granted:** 2018
- **Status:** Active
- **Times cited:** 1
- **Field:** biotech, pharmaceutical

## What it does

This patent describes a way to treat cancer by combining a derivative of nordihydroguaiaretic acid (NDGA)—specifically M4N or maltose-M3N—with a metabolic modulator. A metabolic modulator is a drug that changes how cells process energy, such as rapamycin or everolimus. The key innovation is that these two components work together synergistically, meaning the combined effect is greater than the sum of their individual effects. By targeting the energy metabolism of rapidly dividing cancer cells while simultaneously introducing the NDGA derivative, the treatment aims to shrink tumors and stop them from spreading (metastasis).

## What it does NOT cover

- Does not cover the use of NDGA derivatives alone without a metabolic modulator.
- Does not cover metabolic modulators used in isolation for cancer treatment.
- Does not cover any metabolic modulators outside the specific list provided, such as Ly294002, rottlerin, dichloroacetate, rapamycin, everolimus, or temsirolimus.
- Does not cover non-pharmaceutical or non-synergistic applications of these compounds.

## The clever bit

The patent identifies that cancer cells have unique metabolic requirements that can be exploited; by pairing an NDGA derivative with a metabolic inhibitor, the researchers create a 'double-hit' that prevents the cancer from compensating for the drug's effects.

## Real-world examples

1. Experimental cancer treatments using M4N derivatives
2. Combination therapies involving mTOR inhibitors like everolimus

## Why it matters

This patent represents a shift toward combination therapies in oncology, where researchers look for ways to make existing drugs more potent by pairing them with complementary agents. By leveraging the specific metabolic vulnerabilities of cancer cells, this approach seeks to improve survival rates for common cancers like breast, prostate, and lung cancer. It highlights the ongoing academic and clinical effort to repurpose or enhance plant-derived compounds for modern medical use.

## Frequently asked questions

### What does Using Plant-Derived Chemicals and Metabolic Drugs to Fight Cancer cover?

A medical patent describing a combination therapy that pairs specific plant-derived compounds with metabolic drugs to kill cancer cells more effectively than either could alone.

### Who owns patent US RE46907?

Johns Hopkins University owns this patent, granted in 2018.

### When does this patent expire?

This patent is expected to expire on June 26, 2038, when the invention enters the public domain.

### What is patent US RE46907 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

This patent represents a shift toward combination therapies in oncology, where researchers look for ways to make existing drugs more potent by pairing them with complementary agents. By leveraging the specific metabolic vulnerabilities of cancer cells, this approach seeks to improve survival rates for common cancers like breast, prostate, and lung cancer. It highlights the ongoing academic and clinical effort to repurpose or enhance plant-derived compounds for modern medical use.

### What does this patent NOT cover?

Does not cover the use of NDGA derivatives alone without a metabolic modulator.

**Full plain-English explainer:** https://patentbrief.org/patent/us/RE46907/descovy-taf-ftc

**Original patent:** https://patents.google.com/patent/USRE46907

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._